Literature DB >> 11574103

Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study.

M Mondelli1, F Sicurelli, C Scarpini, M T Dotti, A Federico.   

Abstract

We report the electrophysiological follow-up of five cerebrotendinous xanthomatosis patients treated for 11 years with chenodeoxycholic acid (CDCA). Nerve conduction velocity (NCV) was reduced in three cases. P100 latency of visual evoked potentials was delayed in four cases, interpeaks I-III and I-V of brainstem auditory evoked potentials (BAEPs) was increased in two and interpeak N13-20 of upper limb somatosensory evoked potentials (SEPs) was slowed in one. After 4 months of therapy with CDCA, NCV was normal and did not show any significant change during the 11 years of observation. Central motor conduction time of motor evoked potentials (MEPs) and N24-P40 interpeak latency of lower limb SEPs were increased in five and four cases, respectively, in spite of 2/3-year treatment with CDCA. Improvement of evoked potentials, especially of MEPs and SEPs, was slower and continued over the whole 11-year period. The size of xanthomas slightly decreased in some patients during treatment and the clinical manifestations stabilized, avoiding progressive worsening, but there was no significant improvement in neurological deficit. Two sisters of patients who never took CDCA showed progressive worsening of clinical manifestations, upper limb SEPs and BAEPs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574103     DOI: 10.1016/s0022-510x(01)00563-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

1.  A useful multi-analyte blood test for cerebrotendinous xanthomatosis.

Authors:  Andrea E DeBarber; Jenny Luo; Roberto Giugliani; Carolina F M Souza; John Pei-Wen Chiang; Louise S Merkens; Anuradha S Pappu; Robert D Steiner
Journal:  Clin Biochem       Date:  2014-04-21       Impact factor: 3.281

2.  Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid.

Authors:  F Ginanneschi; A Mignarri; M Mondelli; G N Gallus; M Del Puppo; S Giorgi; A Federico; A Rossi; M T Dotti
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

3.  Liver transplantation due to cerebrotendinous xanthomatosis end-stage liver disease.

Authors:  Cong-Huan Shen; Zheng-Xin Wang
Journal:  World J Pediatr       Date:  2018-05-23       Impact factor: 2.764

4.  Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment.

Authors:  Andrea E DeBarber; Limor Kalfon; Ayalla Fedida; Vered Fleisher Sheffer; Shani Ben Haroush; Natalia Chasnyk; Efrat Shuster Biton; Hanna Mandel; Krystal Jeffries; Eric S Shinwell; Tzipora C Falik-Zaccai
Journal:  J Lipid Res       Date:  2018-08-22       Impact factor: 5.922

5.  Spinal form cerebrotendinous xanthomatosis patient with long spinal cord lesion.

Authors:  Ryuta Abe; Yoshiki Sekijima; Tomomi Kinoshita; Tsuneaki Yoshinaga; Shingo Koyama; Takeo Kato; Shu-Ichi Ikeda
Journal:  J Spinal Cord Med       Date:  2016-02-25       Impact factor: 1.985

6.  Nationwide survey on cerebrotendinous xanthomatosis in Japan.

Authors:  Yoshiki Sekijima; Shingo Koyama; Tsuneaki Yoshinaga; Masayoshi Koinuma; Yuji Inaba
Journal:  J Hum Genet       Date:  2018-01-10       Impact factor: 3.172

7.  Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.

Authors:  Maria Del Mar Amador; Marion Masingue; Rabab Debs; Foudil Lamari; Vincent Perlbarg; Emmanuel Roze; Bertrand Degos; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2018-03-20       Impact factor: 4.982

8.  Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis.

Authors:  A Mignarri; S Rossi; M Ballerini; G N Gallus; M Del Puppo; P Galluzzi; A Federico; M T Dotti
Journal:  J Neurol       Date:  2010-11-21       Impact factor: 4.849

Review 9.  Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders.

Authors:  Melissa D Svoboda; Jill M Christie; Yasemen Eroglu; Kurt A Freeman; Robert D Steiner
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-10-05       Impact factor: 3.908

Review 10.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.